Aim: To evaluate the long-term cost-effectiveness of a Patient Empowerment Programme (PEP) for type 2 diabetes mellitus (DM) in primary care.
rarely sourced from patient-level population data. None of these studies were carried out on an Asian population so a population-based, cost-effectiveness study on an Asian population should be a useful addition to the literature.
The Hong Kong (HK) Hospital Authority (HA), which manages all publicly funded hospitals in HK, launched a Patient Empowerment Programme (PEP) in 2010 for subjects with type 2 DM who attend public general outpatient clinics (GOPCs) for their diabetes care. A detailed description of the PEP has been published elsewhere. [18] [19] [20] [21] [22] [23] [24] Briefly, enrolled subjects attend generic education sessions that cover the importance of self-management and behaviour modification, diet, exercise, stress, coping skills and problem-solving. They also attend disease-specific sessions covering knowledge of DM as well as DM management and self-care. Each PEP session is facilitated by an appropriately trained healthcare professional such as a nurse or social worker, but the non-government organizations (NGOs) who run the sessions can choose their own level of staff and have some freedom in the style of their programmes. Apart from the PEP, most of the subjects with type 2 DM who attend public clinics have also been enrolled in a Risk Assessment and Management Programme for DM (RAMP-DM) which provides regular check-ups and screening for complications and serves as their routine DM care. 25 We previously conducted a 5-year cost-effectiveness analysis (CEA) based on empirical data which estimated that the cost to prevent one death from any cause for someone in the PEP programme was US $14 465 (HK $112 827) when compared with those enrolled only in RAMP-DM. 26 This cost to prevent one death is far below estimates of the statistical value of life in HK-at least HK $10 million 27 -which itself is a relatively low statistical value of life. However, this previous CEA did not evaluate the long-term impact of PEP on healthcare costs over the lifetime (i.e. from the subject's current age until death). In the current study we aimed to conduct a simulation study based on empirical data to estimate the long-term cost-effectiveness of PEP.
| MATERIALS AND METHODS
We used empirical data on the programme cost, incidence of diabetic complications and mortality during the 5-year PEP follow-up, obtained other parameters from the RAMP-DM programme, and incorporated these into a long-term model to simulate the lifetime impact of PEP plus RAMP-DM on the healthcare costs and health-related quality of life of participants versus those who participated in RAMP-DM only but not PEP. These empirical data were derived from a matched cohort of subjects with RAMP plus PEP and subjects with RAMP only, whose characteristics did not differ between the groups. 26 A societal perspective was taken in this CEA. All the costs are in US dollars (1 US $ = 7.8 HK $).
2.1 | The long-term model structure (UKPDS) outcome model was used as a reference to develop our model structure. 28 Each individual began in the no-complication state, with age and sex randomly allocated from the distributions in the empirical data of a matched group of PEP and non-PEP subjects ( Figure 1 ). Each yearly transition could include an initial occurrence of any of the six DM complications, that is, acute myocardial infarction (AMI), other ischemic heart disease (IHD), heart failure, stroke, end-stage renal disease (ESRD) or sight-threatening diabetic retinopathy (STDR). In each year, an individual's probability of developing any of the complications or of dying were calculated based on the individual's profile. After developing any complication(s), the subject would have a higher risk of death in the event year, according to the risk associated with that complication, or they would survive the event year but enter the next cycle with the history of the complication for all subsequent years. Subjects with a history of a complication had a higher chance of death compared to those without. If a death event occurred, the accumulated quality-adjusted life years (QALYs) and cost were calculated for that subject, while a subject who survived that cycle would carry on to the next with an updated age and complication history (if relevant). We simulated only the first development of any specific complication but a subject could have a first event of a different complication, even in the same year.
All transition probabilities were estimated from the empirical data as described later in greater detail.
Costs of healthcare utilization and utility values were applied in each cycle (i.e. each year) according to the health states of individual subject (see later). When every individual in the model had died, total costs and QALYs gained were summed across the group. The simulation was repeated 10 000 times for both PEP and non-PEP groups. The probabilities of developing the six DM complications were based on the incidence rates from matched PEP and non-PEP cohorts over a 5-year follow-up. The detailed subject selection and propensity score matching has been reported elsewhere. 26 Sex-specific incidence rates of complications per person-year were calculated by dividing the 5-year cumulative number of events by the total person-years at risk in the follow-up period for each type of complication in the PEP and non-PEP groups (Table 1 ). The incidence rates were converted into an average annual transitional probability (P) for a subject aged 65 years, i.e. average age in the middle year of the follow-up period, by
where r is the average incidence rate over 5 years and t = 1 for annual probability. 29 Because age and sex were found to be associated with different risks of DM complications, 28, [30] [31] [32] [33] we investigated the association between age and the development of each complication by sex for the matched PEP and non-PEP groups using multivariable Cox proportional hazard regression models (Table 1 ). The hazard ratios for age were applied to the incidence rate (r) to estimate age-specific rates (r age ) using
and the transitional probability (P age ) for a specific age would be
where t is the period of time for which t = 1 for annual probability estimation.
| Mortality
The mortality rates used in the model were based on the subject's age, sex and presence of complications, and the coefficients for the association with mortality were from the RAMP-DM data using four statistical models to estimate mortality rates: (1) rate of death in each year for subjects who have not yet developed any of the six complications, (2) rate of death in an event year for subjects without history of complications, (3) rate of death in an event year for those who have other pre-existing complications, and (4) rate of death in a non-event year
for subjects who have developed complications previously (Table S1 in Supporting information). 34 Probability of death occurring in non-event years (models 1 and 4) was estimated using Gompertz models. The probability of death at age (t) for a subject was estimated by
where H (t│x j ) = h 0 (t) exp (β i x i ) with baseline hazard h 0 (t) = exp (γt) exp (β 0 ) and the parameters γ, β 0 and β i were the coefficients for each factor as shown in Table S1 . For probability of death in event years
(models 2 and 3), logistic models were used. The probability of death was estimated by
where z = β0 + β1 x1 + β2 x2 +…βn xn and β was the coefficient for each factor.
| Estimation of health utility scores
QALYs were used as the long-term outcome in the CEA model. The disease-related health state utility values were taken from RAMP-DM data and the same cross-sectional sample as used for the private medical costs (see later). 35 The health-related quality of life (HRQOL) data were collected using the SF-12v2 health survey and were transformed into SF-6D health utility scores using a local algorithm. 36, 37 Ordinary least squares (OLS) regression was used to estimate the association between each type of DM complication and SF-6D health utility scores, adjusted for socio-demographic factors and clinical parameters (Table 1 ). We applied the utility value of DM without complications and utility decrements according to individual health status. The loss in utility due to multiple complications was assumed to be additive. No agerelated health utility values were applied. The QALYs were calculated by multiplying the utility values with the time spent in that health state.
Details of utility decrements associated with DM complications were obtained from published literature. 38 
| Estimation of costs 2.4.1 | Programme cost
An in-depth costing of the PEP was conducted from a societal perspective and is described elsewhere. 26 The costs included the operational costs of the NGOs providing the service, the administrative costs of the HA head office and cluster office, subjects' and accompanying persons' travel and time cost for attending the PEP sessions, and community resources needed to run the programme which covers the value of volunteer workers' time and of "free" venues for holding sessions. The average of the annualized costs during the study period was converted to the 2017 cost using the Consumer Price Index (CPI) rate 39 and was US $276 per subject. It was assumed to be a one-off cost and was applied to each PEP subject at the initial stage of the model.
| Cost of health service utilization
The cost of public health service utilization included the costs of hospitalization, GOPC visits, specialist outpatient clinic visits, allied health clinic visits, and accident and emergency department visits.
Data from the RAMP-DM cohort of 128 309 subjects over 5 years were used to estimate the incremental cost because of DM complications in the event and subsequent years and corresponding cost multipliers (Table 2) . 35 The cost multipliers were applied to the baseline cost to calculate the extra cost due to increases in age as well as sex grouping and presence of complications. For example, the annual utilization cost for a 65-year-old female with a new AMI and history of heart failure was calculated as US $1650 × 1.02 (65-63) × 1.01 × 4.50 × 2.10 = US $16 385. It was assumed that the age-and sex-related utilization cost was the same for PEP and non-PEP subjects.
The cost of private medical care included outpatient clinics, inpatient stays and self-financed drugs, and was estimated from a cross-sectional survey of 1275 RAMP-DM subjects. 35 Cost multipliers for age, sex and DM complications were generated using the same methods as described for the public healthcare costs and the values are shown in Table 2 . The cost multipliers were derived from the empirical data from people who may or may not have used 
| Cost-effectiveness analysis
All future costs and QALYs were discounted at 3.5% per year. In the base-case model, the effect of PEP was assumed to last for 
| Sensitivity analyses
Sensitivity analyses were conducted to test assumptions on the duration of PEP effect and uncertainties around the parameters. Two alternative assumptions about duration of effect were: (1) a 3-year effect, and (2) a lifelong effect. One-way sensitivity analyses were used to identify which parameters had the largest effects on costeffectiveness. One model parameter was varied at a time while the others remained unchanged. The variables tested included discount rates, programme cost, cost multipliers for public and private health Abbreviations: AMI, acute myocardial infarction; CI, confidence interval; ESRD, end-stage renal disease; IHD, ischaemic heart disease; NA, not applicable; QALYs, quality-adjusted life-years; STDR, sight-threatening diabetic retinopathy.
service use, effectiveness of PEP versus non-PEP for each complication, and utility values (Tables 1 and 2 ). The results are displayed as Tornado Charts. Probabilistic sensitivity analysis was conducted to capture the uncertainties around some of the parameters using the same variables and ranges as in the one-way sensitivity analyses (Tables 1 and 2) . Random values from the distribution of the selected parameters were used in each iteration of the model. The model was repeated 1000 times for 1000 individuals simulated in the model, selecting random values for each parameter each time. The results were plotted on a cost-effectiveness plane and are displayed with cost-effectiveness acceptability curves. All the above sensitivity analyses were based on the CEA model from a societal perspective.
3 | RESULTS
| Base case results
The lifetime cost, from a societal perspective and assuming a 5-year intervention effect, for the PEP group was US $30 621 with nearly 90% of the cost derived from public health service use. For the non-PEP group, the lifetime cost was US $30 423 (Table 3 ). The incremental cost and QALYs gained for the PEP versus non-PEP group were US $197 and 0.06 QALYs, respectively, per subject. This gives an ICER of US $3290 per QALY gained for PEP.
| Sensitivity analysis
The scenario analysis showed that PEP remained consistently costeffective when a shorter (3-year) duration of effect was assumed. The ICER for the 3-year effect model slightly increased to US $6675 per QALY gained from the base-case scenario of a 5-year effect, while that for the lifelong effect model reduced to US $478 per QALY gained ( Table 3) .
The results of other one-way sensitivity analyses showed that the ICER varied from US $478 to US $7897 (Figure 2 ). Varying staff cost had the greatest impact on the ICER among those cost parameters tested, and the assumed duration of the PEP effect had the biggest impact among the effectiveness parameters tested. However, none of the above analyses would change the conclusion that PEP was cost-effective at the stated threshold value of US $46 153 per QALY.
The results of the probabilistic sensitivity analysis are shown as a cost-effectiveness plane ( Figure S1 ). More than half of the estimated ICERs fall below the WTP threshold of US $46 153 (dotted line), but 15.6% of the simulations are located in the south-east quadrant, indicating that PEP is cost-saving with QALYs gained compared with no PEP. The cost-effectiveness acceptability curve (Figure 3) shows that the PEP intervention had a 37% probability of being cost-effective even under the assumption of zero willingness to pay (US $0) for a QALY gained, increasing to 66% probability of being cost-effective at the WTP threshold of US $46 153 for a QALY. The likelihood of PEP being cost-effective remains even when the value of a QALY is lowered to US $40 000 or raised to US $80 000.
| DISCUSSION
In this lifetime model, we found that if the PEP effect lasted for 5 years then PEP was highly cost-effective from a societal perspective One strength of this study is that all the parameters were based on local population data, either from our PEP cohort or from the RAMP-DM data, which eliminates the uncertainty of adapting overseas data to the local population. To validate the model, we compared the observed complication events in the empirical data with the events predicted in the first 5 years from the CEA model. This showed that the probability of developing heart failure could have been overestimated in the model for both the PEP and non-PEP groups but the overall validity of the model was reasonable with overlapping of the 95% CIs for predicted and actual complication rates (Table S2 ).
There were some limitations in our model. The transition probabilities of complications were based on empirical data from the cohort and some of the complication incidence rates were not significantly different between the PEP and non-PEP groups because the number of cases was small (e.g. for ESRD). Also, in order to identify two comparable groups of PEP and non-PEP subjects, we matched two larger groups on several criteria. Although these matched groups were similar in all observed demographic and clinical risk factors at baseline, we cannot exclude differences in unobserved characteristics, but we have no reason to think these existed. In general, the results show that PEP is probably cost-effective but with a 66% likelihood at the threshold of US $46 153 per QALY.
This indicates that there are wide ranges for some parameters used in the model, and some sets of estimates result in PEP not being costeffective. One important set of parameters that contributes to this uncertainty is the hazard ratios for the diabetic complications suffered by the PEP and non-PEP groups. Several of the estimates were not significantly different between the groups and the 95% CIs were wide.
The impact of uncertainty on the hazard ratios was also reflected in the cost-effectiveness plane which shows a number of ICERs located in the north-west or south-west quadrant, indicating no benefit for the PEP group compared with the non-PEP group. Future research will be worthwhile to identify any sub-group that is less probable to benefit from PEP, e.g. by sex or smoking status, and also to see whether there might be an optimum number of PEP sessions to generate an effect on outcomes.
Compared to the three long-term cost-effectiveness studies identified from our systematic review, [14] [15] [16] our PEP programme was different in educational components and educators. Also, unlike our study which applied the observed transition probabilities of the development of complications derived from our empirical data into a long-term model, those three studies applied the observed changes in surrogate outcomes (HbA1c, blood pressure) from randomized controlled trials to predict the transition probabilities of diabetic complications. Those three studies also found that the selfmanagement education programmes were probable to be costeffective in the long term. Similar to this study, Gillett et al. 14 found that their diabetes education and self-management programme (DESMOND) for ongoing and newly diagnosed cases of type 2 DM had a 66% (based on trial) to 70% probability of being cost-effective when compared to usual care.
In conclusion, given the carefully measured cost of PEP and the potentially large benefits, PEP could be highly cost-effective from a societal perspective with ICERs below the WTP threshold of 1 × per capita GDP. 
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